Live webinars focus on Ophthalmic, Wound Care, Podiatry, and Orthopedic Indications using Cryopreserved Human Birth Tissue
Miami, Fla. – April 21, 2020 – TissueTech, Inc., the pioneer in the development and clinical application of regenerative human birth tissue products and parent company of Amniox Medical, Inc. and Bio-Tissue, Inc., announced today that they have rolled out additional live virtual Professional Education (Pro Ed) webinars to take place throughout April, May and June.
The company’s virtual Pro Ed programs kicked off earlier in March when Amniox pivoted their New Orleans National Pro Ed Symposium to a live virtual event in an effort to help prevent the spread of the COVID-19 virus.
“The attendance and feedback from our first event was tremendous, and what we keep hearing from our customers is a genuine need that most for them have during these tumultuous times is to provide additional education and training opportunities for them and their staff,” said Tom Williamson, TissueTech Chief Commercial Officer. “It is clearly evident that there is a demand for this and as such, we’ve expanded the scope and frequency of our Pro Ed events offered to help meet this need.”
Bio-Tissue Pro Ed webinar topics include the treatment of ocular surface diseases and indications including corneal ulcers and mechanical dry eye. To view the full list of Bio-Tissue events and topics, visit www.biotissue.com/events. Amniox topics include advanced complex wound care and reconstruction, tendon repair, total ankle arthroplasty, calcaneal fractures, and the treatment of non-healing chronic wounds. To view the full list of Amniox events and topics, visit https://amnioxmedical.com/events/. All times are noted in Eastern Standard Time.
|Title of Program||Date and Time||Facilitator||Description|
|Calcaneal Fractures||April 23/1:00pm – 2:00pm||Ryan Putnam, MD||Register now for this LIVE webinar featuring Ryan Putnam, MD, to learn how cryopreserved umbilical cord allografts can help expedite wound healing and functional recovery when applied as a surgical barrier in calcaneal fracture repairs.|
|Best Practices for Coding and Billing with PROKERA||April 23 & May 21/4:00pm – 5:00pm||John Rumpakis, OD||This webinar will be hosted by Dr. John Rumpakis, OD who is an expert in billing and coding in the ocular space. He will cover the reimbursement landscape, how to code for ocular surface disease and where PROKERA fits in the reimbursement guidelines.|
|Treating EBMD and OSD Prior to Cataract Surgery||April 28/11:00am – 12:00pm||Neel Desai, MD||Cataract surgery is one of the most pervasive procedures done by ophthalmologists today. This webinar will cover how treating ocular surface disease prior to cataract surgery will yield more accurate biometry readings and ultimately better results.|
|The Latest Clinical & Scientific Research Developments of Cryopreserved Amniotic Membrane Therapy||April 30/11:00am – 12:00pm||Scheffer Tseng, MD, PhD||Dr. Scheffer Tseng has researched and published peer-reviewed articles on the benefits of amniotic membrane for 34 years. Learn about the latest scientific research and clinical applications on cryopreserved amniotic membrane therapy with this live webinar.|
|Corneal Nerve Regeneration Journal Club||May 7/1:00pm – 2:00pm||Thomas John, MD & Pedram Hamrah, MD||Nerves play a major impact in a variety of indications. This webinar details some learnings gathered through multiple studies on how cryopreserved amniotic membrane effects corneal nerve density and sensitivity.|
|Live-Virtual Pro Ed Symposium: Wound Care||May 9/9:00am-11:30am||Mark Gould, MD, Allen Raphael, DPM, and others to be announced||Learn how cryopreserved amniotic membrane and umbilical cord is currently being used to help orchestrate a healing environment with chronic and complex wounds.|
About TissueTech, Inc.
TissueTech, Inc., is the pioneer in the development and clinical application of human birth tissue-based products. Founded in 1997, Bio-Tissue markets products for the ophthalmology and optometry markets; and Amniox markets products for use in the musculoskeletal and wound care markets. Clinicians have performed more than 500,000 human implants with the company’s products and published more than 360 peer-reviewed studies supporting its technology platform. The Company’s first product, AmnioGraft®, is the only tissue graft designated by the FDA as homologous use as acting as an anti-scarring, anti-inflammatory and anti-angiogenic agent and supporting epithelial adhesion and differentiation on the ocular surface. Learn more at https://tissuetech.com/.
Physicians are encouraged to visit the TissueTech Physician Portal to learn more about TissueTech’s platform technology, review product application guides, and view educational webinars.